Devyser Diagnostics AB

DVYSR

SE0016588867

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 09:45:28 2024-12-05 am EST			5-day change	1st Jan Change
122.00 ^SEK	-0.81%		-7.58%	+55.22%

Dec. 02	Pareto makes three changes to Swedish portfolio after underperformance in November	FW
Dec. 02	Devyser receives Class D IVDR approval for groundbreaking RHD test	FW

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Devyser Diagnostics AB

Pareto makes three changes to Swedish portfolio after underperformance in November	Dec. 02	FW
Devyser receives Class D IVDR approval for groundbreaking RHD test	Dec. 02	FW
Devyser Achieves Class D IVDR Approval for its RHD Product	Dec. 02	CI
Pareto reiterates Buy for Devyser after Capital Markets Day	Nov. 26	FW
Pareto shakes up its Swedish portfolio	Nov. 01	FW
Pareto Securities lowers target price for Devyser to SEK 160 (165), reiterates Buy	Oct. 31	FW
Carnegie lowers target price for Devyser to SEK 143 (145), reiterates Buy - BN	Oct. 31	FW
Devyser's CEO Fredrik Alpsten buys shares for SEK 0.5 million	Oct. 30	FW
Devyser Diagnostics AB, Q3 2024 Earnings Call, Oct 30, 2024	Oct. 30
Devyser increases sales but decreases operating profit	Oct. 30	FW
Devyser Diagnostics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Oct. 30	CI
Devyser Enters Collaboration to Secure US Approval for Kidney Transplant Monitoring Test	Oct. 29	MT
Devyser aims to secure FDA approval for monitoring product	Oct. 29	FW
Devyser Enters into Agreement with Thermo Fisher Scientific to Collaborate on Obtaining U.S. Food and Drug Administration Approval for One Lambda? Devyser Accept Cfdna	Oct. 29	CI
Devyser receives regulatory approval for Devyser Compact in China	Oct. 28	FW
Devyser Diagnostics AB Achieves Class III Approval in China	Oct. 28	CI
Carnegie sees growth in Devyser's portfolio - raises target price	Oct. 15	FW
Carnegie raises target price for Devyser to SEK 145 (135), reiterates Buy - BN	Oct. 15	FW
Business World stays at a neutral advice for Devyser	Oct. 11	FW
Devyser expected to have increased sales 16 percent in Q3 - Redeye	Oct. 11	FW
Devyser terminates liquidity guarantee agreement with Carnegie	Oct. 09	FW
Nordea raises target price for Devyser to SEK 140 (125), reiterates Buy	Oct. 01	FW
Pareto initiates with buy for Devyser (update)	Sep. 25	FW
Pareto Securities initiates coverage of Devyser with Buy and target price SEK 165	Sep. 25	FW
Devyser to present new innovations and studies in transplantation at conference	Sep. 24	FW

Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnosticsâ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.

Employees

119

Sector

Biotechnology & Medical Research

Calendar

2025-02-12 - Q4 2024 Earnings Call

More about the company